Skip to content
ClinCalc Pro
Menu
Synthetic anabolic androgen (gonadotrophin inhibitor)

Danazol

Brand names: Danol

Danazol is a synthetic androgen derivative with anti-gonadotrophic activity used in endometriosis, benign fibrocystic breast disease, and hereditary angioedema.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It suppresses the pituitary release of gonadotrophins and has weak androgenic effects, reducing ovarian hormone production and inducing an anovulatory, hypo-oestrogenic state.

Prescribing in practice

  • It can cause androgenic adverse effects including weight gain, acne, hirsutism, and voice deepening, some of which may be irreversible, so women should be warned and treatment reviewed if virilisation occurs.
  • It is contraindicated in pregnancy because of the risk of virilising a female fetus, and effective non-hormonal contraception must be used throughout treatment.
  • Use with caution where there is hepatic impairment, cardiac or renal disease, or a history of thromboembolism, and avoid in undiagnosed abnormal genital bleeding.

Monitoring

Monitor liver function during treatment and watch for androgenic effects, weight gain, and signs of thromboembolism.

Counselling the patient

  • Report any deepening of the voice promptly, as this change may not fully reverse.
  • Use a reliable non-hormonal method of contraception, and stop the medicine and seek advice if you think you may be pregnant.
  • Tell your doctor about any abdominal pain, jaundice, or unusual swelling.

Evidence & guidelines

Danazol is an established but second-line hormonal treatment for endometriosis, generally reserved for when better-tolerated options are unsuitable because of its androgenic adverse-effect profile.

Reference: SmPC Danol; ESHRE Endometriosis Guideline 2022; HAE UK Consensus Document; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.